Research comparison
Hexarelin vs Ipamorelin
A side-by-side look at two of the most studied growth hormone secretagogues in laboratory research — covering receptor selectivity, downstream hormone profile, half-life, and what each one is typically used to model.
Hexarelin
Hexapeptide · GHS-R1a + CD36
Ipamorelin
Pentapeptide · GHS-R1a selective
At-a-glance comparison
| Property | Hexarelin | Ipamorelin |
|---|---|---|
| Compound class | Hexapeptide GH secretagogue | Pentapeptide GH secretagogue |
| Primary receptor | GHS-R1a + secondary CD36 binding | GHS-R1a (highly selective) |
| Relative GH-release potency (in vitro) | Highest of the GHRP family | Moderate, comparable to GHRP-2 at lower doses |
| Cortisol response | Elevated | Negligible |
| Prolactin response | Elevated | Negligible |
| ACTH response | Elevated | Minimal |
| Plasma half-life | ~55 minutes | ~2 hours of bioactivity (rapid initial clearance) |
| Receptor desensitization (repeat dosing) | Faster onset reported | Slower, preserves pulsatility longer |
| Reported cardiac-tissue interaction | Documented (CD36-mediated) | Not characterized |
| Typical research pairing | Standalone, short protocols | Paired with CJC-1295 for synergistic GH/IGF-1 modeling |
| Reconstitution | Bacteriostatic water, refrigerated post-mix | Bacteriostatic water, refrigerated post-mix |
Mechanism of action
Both Hexarelin and Ipamorelin are growth hormone-releasing peptides (GHRPs) that agonize the growth hormone secretagogue receptor (GHS-R1a) on somatotroph cells in the anterior pituitary. Receptor activation stimulates pulsatile GH release independent of the GHRH pathway, and the two can be modeled additively in vitro.
Hexarelin is the more potent GH releaser of the two, but it also engages CD36 receptors in cardiac and vascular tissue and triggers measurable cortisol, ACTH, and prolactin release. Ipamorelin is structurally cleaner — at standard research doses it leaves cortisol and prolactin essentially unchanged, which is why it's the preferred reference compound when isolating GH-axis effects.
Research applications
- Hexarelin — preferred where strong, short-window GH spikes are needed, or in cardiac/CD36 receptor studies.
- Ipamorelin — preferred for long-protocol GH/IGF-1 modeling, hormone-axis selectivity studies, and CJC-1295 synergy work.
Half-life and dosing window
Hexarelin's reported plasma half-life of approximately 55 minutes produces a sharper, shorter GH pulse than Ipamorelin's ~2-hour bioactivity window. For protocols that aim to mimic endogenous pulsatility, Ipamorelin is generally the better-tolerated choice on repeat administration because of its slower desensitization profile.
Frequently asked questions
What is the main difference between Hexarelin and Ipamorelin in research models?
Hexarelin is a more potent GH secretagogue but consistently elevates cortisol and prolactin in published in vitro and animal data, while Ipamorelin shows highly selective GH release with negligible cortisol or prolactin response.
Which peptide has a longer half-life?
Hexarelin reports a plasma half-life of roughly 55 minutes in published pharmacokinetic studies; Ipamorelin is shorter at approximately 2 hours of bioactivity but with a faster initial clearance window of ~30 minutes.
Do Hexarelin and Ipamorelin act on the same receptor?
Both are agonists of the growth hormone secretagogue receptor (GHS-R1a). Hexarelin shows additional binding affinity at CD36 receptors implicated in cardiac tissue studies; Ipamorelin is considered a cleaner GHS-R1a-selective ligand.
Is desensitization a concern in repeated-dosing research protocols?
Published rodent literature reports more rapid receptor desensitization with Hexarelin under continuous administration; Ipamorelin protocols tend to preserve responsiveness across longer pulsatile windows.
For research use only
All FH Supplements peptides are sold strictly for in vitro laboratory research. Not for human or veterinary use. Every batch ships with a third-party certificate of analysis.